Solomon M. Adams, PharmD, a TL-1 Post-Doctoral scholar and PhD candidate in the Department of Pharmaceutical Science at the University of Pittsburgh School of Pharmacy, recently authored a review in the journal Pharmacogenomics. The article, titled, “The Pharmacogenomics of Severe Traumatic Brain Injury.” The review discusses the role of precision pharmacotherapy through the use of genomic data (pharmacogenomics) in patients with severe TBI. The paper further discusses the role of pharmacogenomics as a tool improve care for patients suffering from the long-term effects of severe TBI, and its role in drug development. This is one of the first discussions of pharmacogenomics in the context of severe TBI. The review was coauthored by collaborators at the Safar Center and written under the direction of senior author, Philip E. Empey, PharmD, PhD.